Five Reasons Why GSK Spinning Off Consumer Is Not So Straightforward
Executive Summary
GSK once again provided grist to the stock market rumor mill over the weekend, with reports emerging that its chairman has been talking to major shareholders about the possibility of splitting up the company. But there are reasons to doubt whether talks would lead to action any time soon.
You may also be interested in...
Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal
LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.
Oral Care Drives OTC Sales As Glaxo Buffs Its Consumer Health Shine
GlaxoSmithKline consumer health sales grow 3% at constant exchange rates during the second quarter driven by Sensodyne oral care and medicated skin care products. CEO Emma Walmsley dismisses rumors of divesting the business, saying firm continues to see “very good potential for growth and performance” of consumer health.
Oral Care Drives OTC Sales As Glaxo Buffs Its Consumer Health Shine
GlaxoSmithKline consumer health sales grow 3% at constant exchange rates during the second quarter driven by Sensodyne oral care and medicated skin care products. CEO Emma Walmsley dismisses rumors of divesting the business, saying firm continues to see “very good potential for growth and performance” of consumer health.